Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by wm23fouron Feb 11, 2022 1:31pm
157 Views
Post# 34420953

RE:RE:RE:Not encouraging

RE:RE:RE:Not encouraging Thanks, watchman.  I dont expect it to happen either. .Plus, if as you say, everyone gets 6 months advance notice, that for all practical purposes elimintates risk of EUA ending for rapid tests. Would surely think we'll get this submitted within 6 months, like say, if advance notice was given tomorrow.     

What I was thinking about though is maybe a little different than the situation you mentioned. Maybe I worded my concern incorrectly?   Dont mean to split hairs, but look what happened to SONA.    Sona Nanotech Receives 'Deprioritization' from FDA; Health Canada Evaluation Continues | 2020-10-29 | Press Releases | Stockhouse 

Looks to me that in above case FDA simply made the decision to "deprioritize" that Co's EUA application for their rapid test.  No 6 month advance warning.  FDA says they didnt refuse EUA due to test performance.  Looks to me that FDA just deprioritized their submission for EUA out of the blue.  It was my understanding Sona could still apply for regular (non EUA) approval.  I realize extremely low probablity this would ever happen to Acuvid, but we cant say its never happened in past. (When I do DD on a spec stock I analyze all the pro's and con's.  For me the pro's still far outweigh the cons for THRM.  But still, I dont totally disregard a con even if very low probablitity.) 

Lets get this submission and approval completed already.  
<< Previous
Bullboard Posts
Next >>